HRP20161474T1 - Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave - Google Patents
Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave Download PDFInfo
- Publication number
- HRP20161474T1 HRP20161474T1 HRP20161474TT HRP20161474T HRP20161474T1 HR P20161474 T1 HRP20161474 T1 HR P20161474T1 HR P20161474T T HRP20161474T T HR P20161474TT HR P20161474 T HRP20161474 T HR P20161474T HR P20161474 T1 HRP20161474 T1 HR P20161474T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- cancer
- avpal
- phenylalanine
- variant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 | |
| EP08795357.6A EP2175875B1 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| PCT/US2008/009765 WO2009025760A2 (en) | 2007-08-17 | 2008-08-15 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161474T1 true HRP20161474T1 (hr) | 2016-12-30 |
Family
ID=40363135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161474TT HRP20161474T1 (hr) | 2007-08-17 | 2008-08-15 | Sastavi prokariotske fenilalanin amonij-liaze i metode za liječenje raka koje koriste ove sastave |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7537923B2 (enExample) |
| EP (1) | EP2175875B1 (enExample) |
| JP (1) | JP5584120B2 (enExample) |
| CN (1) | CN101803492B (enExample) |
| AR (2) | AR067972A1 (enExample) |
| AU (1) | AU2008289549B2 (enExample) |
| BR (2) | BR122018072594B8 (enExample) |
| CA (1) | CA2687028C (enExample) |
| CL (1) | CL2008002390A1 (enExample) |
| CY (1) | CY1118222T1 (enExample) |
| DK (1) | DK2175875T3 (enExample) |
| ES (1) | ES2602618T3 (enExample) |
| HR (1) | HRP20161474T1 (enExample) |
| HU (1) | HUE029510T4 (enExample) |
| LT (1) | LT2175875T (enExample) |
| MX (1) | MX2009012261A (enExample) |
| PE (1) | PE20090605A1 (enExample) |
| PL (1) | PL2175875T3 (enExample) |
| PT (1) | PT2175875T (enExample) |
| RU (2) | RU2009141987A (enExample) |
| SI (1) | SI2175875T1 (enExample) |
| TW (1) | TWI418787B (enExample) |
| WO (1) | WO2009025760A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| EP3025728B1 (en) * | 2010-02-04 | 2018-08-08 | BioMarin Pharmaceutical Inc. | Method for purifying prokaryotic phenylalanine ammonia-lyase variants |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US20150246083A1 (en) * | 2012-07-27 | 2015-09-03 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| SMT201900315T1 (it) | 2013-04-18 | 2019-07-11 | Codexis Inc | Polipeptidi di fenilalanina ammoniaca liasi ingegnerizzati |
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| EP3583946A1 (en) | 2014-04-01 | 2019-12-25 | Rubius Therapeutics, Inc. | Enucleated hematopoietic cells comprising an exogenous antigen |
| CA2943432A1 (en) | 2014-04-16 | 2015-10-22 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| US10752923B2 (en) | 2014-07-14 | 2020-08-25 | Cysbio Aps | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| US20170360900A1 (en) | 2014-12-22 | 2017-12-21 | Codexis, Inc. | Human alpha-galactosidase variants |
| AU2017301600B2 (en) | 2016-07-26 | 2022-08-04 | Biomarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| SG11201906880VA (en) * | 2017-02-13 | 2019-08-27 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| CA3099704A1 (en) | 2018-05-09 | 2019-11-14 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3893860A4 (en) | 2018-12-14 | 2023-03-29 | Codexis, Inc. | ENGINEERED TYROSINE AMMONIA LYASE |
| MX2021007552A (es) | 2018-12-20 | 2021-08-11 | Codexis Inc | Variantes de alfa-galactosidasa humana. |
| KR102884442B1 (ko) | 2019-02-14 | 2025-11-10 | 솜 이노베이션 바이오테크, 에스.에이. | 페닐케톤뇨증 치료에 사용하기 위한 트리암테렌 또는 놀라트렉세드 |
| MX2022001515A (es) * | 2019-08-07 | 2022-04-06 | Rakuten Medical Inc | Composiciones de conjugado de cetuximab-ir700. |
| MX2022002473A (es) | 2019-08-30 | 2022-08-02 | Codexis Inc | Variantes de lipasa modificadas geneticamente. |
| PE20221266A1 (es) | 2019-12-20 | 2022-08-16 | Codexis Inc | Variantes de alfa-glucosidasa acida disenadas por ingenieria |
| BR112022015139A2 (pt) | 2020-02-04 | 2022-10-11 | Codexis Inc | Polipeptídeo da leucina descarboxilase engenheirada, composição, sequência de polinucleotídeo engenheirado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da leucina descarboxilase engenheirada e para tratar e/ou prevenir os sintomas de doença da urina de xarope de bordo, composição, e, uso |
| AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
| CA3191867A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
| WO2022047264A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| EP4341394A4 (en) | 2021-05-19 | 2025-04-09 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| JP2024540358A (ja) | 2021-11-01 | 2024-10-31 | シンティス バイオ，インコーポレイティド | 工学操作ロイシン脱炭酸酵素 |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| TW202521161A (zh) | 2023-11-17 | 2025-06-01 | 美商拜奧馬林製藥公司 | 苯丙胺酸解氨酶與ｐｏｅｇｍａ之結合物及其使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| ES2184756T3 (es) | 1992-11-19 | 2003-04-16 | Anticancer Inc | Uso de metioninasa como agente antitumoral en quimioterapia antimetionina. |
| JP4007516B2 (ja) | 1992-12-04 | 2007-11-14 | ロバーツ，ジョゼフ | 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用 |
| DK75593D0 (enExample) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| AU718439B2 (en) | 1995-09-21 | 2000-04-13 | Genentech Inc. | Human growth hormone variants |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| JP4812167B2 (ja) | 1999-02-12 | 2011-11-09 | モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド | 薬物輸送用マトリックス、ならびにその作成方法および使用方法 |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| CA2406390A1 (en) | 2000-04-14 | 2001-10-25 | University Of South Carolina Research Foundation | Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
| US6967097B2 (en) * | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| IL162811A0 (en) | 2002-02-26 | 2005-11-20 | Du Pont | Method for the recombination of genetic elements |
| US20080124275A1 (en) | 2002-11-14 | 2008-05-29 | The Scripps Research Institute | Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
| WO2006034373A2 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en not_active Ceased
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012134838A (ru) | Композиции прокариотической фенилаланин-аммиак-лиазы и способы лечения рака с использованием таких композиций | |
| Nakada et al. | Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads | |
| Van Golen et al. | Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma | |
| TWI761305B (zh) | 抑制Ｈｉｆ２α基因表現之組合物及方法 | |
| SG11201408810TA (en) | Methods of treating arthritis | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201806134SA (en) | Oncolytic viral vectors and uses thereof | |
| UA77945C2 (en) | Use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders (variants), pharmaceutical composition (variants) | |
| JP2010536759A5 (enExample) | ||
| BRPI0514420A (pt) | peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo | |
| JP2014506135A5 (enExample) | ||
| US9828412B2 (en) | Short peptide targeting EPS8 binding with EGFR and use thereof | |
| CN113993592A (zh) | 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物 | |
| EP3120849A1 (en) | Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer | |
| KR20220003546A (ko) | 티로신 키나제 억제제 저항성 egfr 돌연변이를 지니는 암 세포에 대한 항종양 활성을 갖는 화합물 | |
| KR20220167770A (ko) | 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드-지질의 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물 | |
| KR101454866B1 (ko) | 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도 | |
| EA200800011A1 (ru) | Тиенопиримидиновые и тиенопиридиновые модуляторы киназы | |
| BR0112130A (pt) | Composições farmacêuticas e métodos para uso | |
| SG11201808981XA (en) | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof | |
| USRE45471E1 (en) | Pharmaceutical composition or combination drug | |
| SG11201908932SA (en) | Process for making arylomyin ring analogs | |
| JP7223502B2 (ja) | 医薬組成物 | |
| CN113712955B (zh) | 含铂化合物及其组合物和应用 | |
| CA2634902A1 (en) | Anticancer agent comprising a peptide |